Scientists at Galileo Pharmaceuticals, Inc. have demonstrated a direct relationship between inflammation and glucose levels. Through its recently established metabolic disease program, Galileo confirmed in preclinical models that inhibiting lipoxygenases, known mediators of inflammatory response, significantly lowers blood glucose levels in animal models of diabetes.
"Metabolic disease is a health concern of near-epidemic proportions, particularly in the US," said Lloyd M. Kunimoto, president and chief executive officer of Galileo Pharmaceuticals, Inc. "We are encouraged by our initial study, which confirms the role of inflammation in the regulation of carbohydrate and lipid metabolism, and validates our proprietary drug discovery platform using Conserved Inflammatory Pathway (CIP) modulators to treat a wide variety of important diseases such as asthma, arthritis, diabetes, and other diseases mediated by inflammation."